Chimerix starts Phase II/III trial of heparin-derived blood cancer drug in Covid-19

Chimerix starts Phase II/III trial of heparin-derived blood cancer drug in Covid-19

Source: 
MedCity News
snippet: 

The development of the drug, DSTAT, is based on preclinical research indicating it can inhibit the inflammatory cytokines involved in the cytokine storms that cause much of the morbidity and mortality in Covid-19, as well as addressing the coagulation issues resulting in young patients having strokes.